Intas Pharmaceuticals’ new warning letter from the U.S. FDA reads like a checklist of what not to do when the regulator pays a visit to your manufacturing facility. The FDA handed Intas a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback